Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials

By afschroeder • November 29, 2025

Guttman-Yassky E, Kabashima K, Worm M, Luna PC, Hong HC, Chovatiya R, Bernstein JA, Kern JS, Ehst BD, Magnolo N, Herranz-Pinto P, Stein Gold L, Sofen H, Pink AE, Esfandiari E, Arai T, Yang Y, Shi R, Barragan C, Kricorian G, Schwartz-Sagi L, Bissonnette R. Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials. Lancet. 2025 Nov 25:S0140-6736(25)01865-3. doi: 10.1016/S0140-6736(25)01865-3. Epub ahead of print. PMID: 41314226.

Tags: Dermatology, Olive View DoM, Publications

Initiating Biologics in Atopic Dermatitis: Global Practices and Recommendations from the AMAZE Project

Armstrong AW, Kim HJ, Pink AE, Gorelick J, Rossi M, Trzeciak M, Deleuran M, Nakajima S, Prajapati VH. Initiating Biologics in Atopic Dermatitis: Global Practices[...]

Reply to Botto et al’s “Applicant interview metrics and preference signaling in dermatology: A serial cross-sectional study”

Fleshner L, Chan R, Klufas T, Grant-Kels JM, Zhou AE. Reply to Botto et al's "Applicant interview metrics and preference signaling in dermatology: A serial[...]

Identification of a spatially organized TREM2-associated permissive macrophage niche in human pulmonary tuberculosis alveolar pneumonia

Teles RMB, Benabdessalem C, Perrie J, Wei C, West J, de Andrade Silva BJ, Andrade PR, Mansky LA, Divaka P, Fischbacher L, Lam K, Ma[...]